Table 2.
Linear Multivariable-Adjusted Correlates of Substrate V Degradation as an Outcome and Each Infarct Subtypea
| Model I Substrate V Degradation (n = 304) |
Model II Substrate V Degradation (n = 290) |
Model III Substrate V Degradation (n = 290) |
||||
|---|---|---|---|---|---|---|
| β Estimate (SE) | P Value | β Estimate (SE) | P Value | β Estimate (SE) | P Value | |
| Age, years | −.001 (0.001) | .29 | −.001 (0.001) | .42 | −.001 (0.001) | .47 |
| Female | +.017 (0.020) | .39 | +.023 (0.021) | .28 | +.020 (0.020) | .32 |
| White | +.002 (0.006) | .67 | +.003 (0.006) | .62 | +.003 (0.006) | .56 |
| BMI | −.001 (0.001) | .78 | −.001 (0.001) | .43 | −.001 (0.001) | .46 |
| ApoE4 | +.009 (0.020) | .67 | −.013 (0.020) | .53 | −.027 (0.022) | .22 |
| ACE inhibitor use | +.009 (0.018) | .61 | +.004 (0.020) | .84 | +.001 (0.019) | .95 |
| LV infarct (0, 1, >1) | −.006 (0.019) | .75 | −.009 (0.020) | .64 | −.014 (0.019) | .45 |
| SV infarct (0, 1, >1) | +.031 (0.013) | .02 | +.029 (0.014) | .04 | +.0001 (0.019) | .99 |
| Cardiovascular disease | – | – | +.015 (0.019) | .43 | +.015 (0.019) | .43 |
| Diabetes | – | – | +.036 (0.020) | .08 | +.029 ((0.020) | .14 |
| Hypertension | – | – | +.030 (0.027) | 27 | +.021 (0.026) | .42 |
| ApoE4*SV infarct | – | – | – | – | +.158 (0.034) | <.0001 |
Abbreviations:ACE, angiotensin-converting enzyme; ApoE4, apolipoprotein E4 allele; BMI, body mass index; SV, small vessel.
a
Model I: multivariate linear regression adjusting for age, gender, race, BMI, ApoE4, and ACE inhibitor use to study the relationship between LV and SV infarcts and substrate V degradation as an outcome.Model II: Model I plus the vascular diseases including cardiovascular disease, diabetes, and hypertension.Model III: Model II plus ApoE4*SV infarct = interaction of ApoE4 allele and SV infarct.